The objective of this study is to assess the non-inferiority of the intraparenchymal portal vein covered stent in terms of safety and efficacy for managing portal hypertension and its related complications, in comparison to the currently available TIPS Covered Stent System by GORE.
Age 18-75 years (inclusive); male or non-pregnant female.
Diagnosed with cirrhosis and associated complications of portal hypertension (such as esophageal and gastric variceal bleeding, refractory ascites), and meeting the consensus recommendations for TIPS indications (see Appendix 5).
Participants must understand the purpose of the trial, voluntarily participate, sign an informed consent form, and be willing to complete the follow-up according to the project requirements.
Severe right heart failure, congestive heart failure (LVEF < 40%), or severe valvular heart dysfunction.
Uncontrolled systemic infection or inflammation.
Persistent moderate to severe pulmonary hypertension after treatment (tricuspid regurgitant peak velocity > 3.4 m/s or pulmonary artery systolic pressure > 50 mmHg).
Patients in hepatic encephalopathy coma or comatose phase (West Haven Criteria Stage III, IV).